Abstract
Neonates, most notably prematurely born neonates, are particularly vulnerable to enteric pathogens. It is recommended that all pregnant patients receive antibiotics following Preterm Premature Rupture of Membranes (PPROM) to prolong pregnancy, yet not all antibiotic regimens have been studied for efficacy, especially when considering neonatal outcomes. Here we find, in a clinical cohort of at-risk infants, broad spectrum antibiotic treatment, including cephalosporins, increased the risk of LOS in neonates in comparison to penicillin base treatments. We followed those initial clinical findings with a preclinical model, here showing that prenatal cephalosporin antibiotics, but not penicillins, decreased mammary IgA in dams, and limited the availability of IgA within the lumen of nursing offspring. Decreased IgA correlated with an outgrowth of commensal E.coli and increased colonization and translocation of pathogen E. coli. This increased risk for mortality in a model of LOS that was associated with decreased mammary IgA. We propose maternal administration of select antibiotics could limit maternal IgA availability by disrupting mammary IgA, leading to increased risk of LOS in infants by allowing for pathogen colonization in the neonatal intestine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Pittsburgh gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Metagenomic 16S sequences will be deposited and available in the NIH GenBank SRA database.
